We spoke with Dr. Alex Andrews, CEO of Neurotech International (ASX:NTI), about the great data her company has recently received from a study of its ...







Neurotech (ASX:NTI) has a product to reduce the symptoms for 93% of children with severe autism [EosDXwzjE]

Neurotech (ASX:NTI) has a product to reduce the symptoms for 93% of children with severe autism [EosDXwzjE]

| 1h 28m 28s | Video has closed captioning.

We spoke with Dr. Alex Andrews, CEO of Neurotech International (ASX:NTI), about the great data her company has recently received from a study of its NTI164 product in Autism Spectrum Disorders (ASX) and the potential of the upcoming Phase II/III trial. NTI164 is the first ever first full-spectrum medicinal cannabis product to be successfully studied in children with ASD.

Aired: November 29th 2024

Rating: TV-14

Buy Now:

Problems Playing Video? | Closed Captioning

Related to This Episode

  • Q&A with Heidi Thomas

    Q&A with Heidi Thomas

    Writer & Executive Producer of Neurotech (ASX:NTI) has a product to reduce the symptoms for 93% of children with severe autism [EosDXwzjE] on the secret of the show.

  • Relive the Drama with Gif Recaps

    Relive the Drama with Gif Recaps

    Miss an episode? Catch up on all things Poplar with our gif recaps.

  • Visit the Official Site

    Visit the Official Site

    Dive deeper into Neurotech (ASX:NTI) has a product to reduce the symptoms for 93% of children with severe autism [EosDXwzjE] with cast Q&As, expert blogs, BTS photos, and more!

  • Explore the Modern Midwives Blog

    Explore the Modern Midwives Blog

    Experienced midwives discuss how Neurotech (ASX:NTI) has a product to reduce the symptoms for 93% of children with severe autism [EosDXwzjE] intersects with modern day Midwifery.

Learn About Midwifery Today

Blog

Learn About Midwifery Today

Read the Modern Day Midwives Blog and learn more about our bloggers, all experienced midwives.

Read now